Liver illustration: Shutterstock
November 4, 2024 10:00 AM EST
R&D
Pharma
In Focus

Is there room for MASH drugs in a GLP-1 world?

Max Bayer

Pharma Reporter

For years, drug de­vel­op­ers work­ing to treat an ad­vanced form of fat­ty liv­er dis­ease known as MASH were chas­ing wide-open ter­rain. There were no prod­ucts …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times